MEI Pharma And Kyowa Kirin Announce Data From Ongoing Phase 2 TIDAL Study Evaluating Zandelisib; Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response, 9.9% Of Patients Discontinued Due To Drug Related Adverse Event